Prostate Cancer Indications
March 11, 2022: The investigator meeting for the clinical trial of Respacio® Radiation Protection Hydrogel was successfully held, officially launching the registrational clinical trials for this domestically innovative hydrogel designed for radiotherapy protection in prostate cancer.
August 30, 2022: The first patient enrollment for Phase I of the registrational clinical study of Respacio® Radiation Protection Hydrogel was successfully completed at Peking Union Medical College Hospital in Beijing, with the hydrogel injection and implantation procedure achieving a complete success.
September 23, 2023: The mid-study investigators' meeting for the registrational clinical trial of Respacio® Radiation Protection Hydrogel in prostate cancer was successfully held.
March 11, 2022: The investigator meeting for the clinical trial of Respacio® Radiation Protection Hydrogel was successfully held, officially launching the registrational clinical trials for this domestically innovative hydrogel designed for radiotherapy protection in prostate cancer.
August 30, 2022: The first patient enrollment for Phase I of the registrational clinical study of Respacio® Radiation Protection Hydrogel was successfully completed at Peking Union Medical College Hospital in Beijing, with the hydrogel injection and implantation procedure achieving a complete success.
September 23, 2023: The mid-study investigators' meeting for the registrational clinical trial of Respacio® Radiation Protection Hydrogel in prostate cancer was successfully held.
Product usage diagram
Contact Us
Telephone: 021-51592768
E-mail: cs@reunionmed.com
Address: Floor 2, Building 7, 1630 Yecheng Road, Jiading District, Shanghai
Scan QR Code